Sumner H Burstein PhD
Title | Professor Emeritus |
---|
Institution | University of Massachusetts Medical School |
---|
Department | Biochemistry and Molecular Pharmacology |
---|
Address | University of Massachusetts Medical School 364 Plantation Street, LRB Worcester MA 01605
|
---|
Phone | 508-856-2850 |
---|
vCard | Download vCard |
---|
|
|
|
|
Institution | UMMS - School of Medicine |
---|
Department | Biochemistry and Molecular Pharmacology |
---|
|
|
---|
|
Biography Massachusetts Institute of Technology, Cambridge, MA, United States | BS | | Chemistry | Brandeis University, Waltham, MA, United States | MS | | Chemistry | Wayne State University, Detroit, MI, United States | PHD | | Chemistry |
Overview Academic History BS, Massachusetts Institute of Technology, 1953 PhD, Wayne State University, 1959 Postdoctoral Training Fellow, Weizmann Institute, 1960 Fellow, Brandeis University, 1961
Lipid Mediated Signaling Pathways My current research interest is in the area of bioactive lipid-mediated signaling pathways. N-arachidonoyl glycine (NAGly), an endogenous lipoamino acid, with potential physiological and pharmacological significance, is found at high levels in rat brain, spinal cord and other sites throughout the body. It is the simplest member of a subfamily of the super family of eicosanoids, and comprises more than 50 members. Prior reports had shown that NAGly acts to elicit analgesic properties similar to those reported for the closely related endocannabinoid anandamide. It is a putative ligand for GPR18, a GPCR expressed in spleen, testis and brain where it plays a role in induced cellular migration of cells to sites of damage. Unlike anandamide, NAGly does not bind to either the CB1 or CB2 cannabinoid receptors, and thus exhibits no psychotropic activity. NAGly also displays modest activity as an in vitro inhibitor of FAAH, the enzyme primarily responsible for the inactivation of anandamide under physiological conditions. We do not believe this effect results in anti-inflammatory action. However, NAGly binds with high affinity to GPR18 resulting in a robust increase of the anti-inflammatory eicosanoid PGJ. A growing body of reports indicates a wide range of functional responses for NAGly, however, none address the subject of receptor-mediated signaling pathways. An understanding of the pathways would open the way for the discovery of potent analogs of NAgly that would be candidates for therapeutic agents, which is my long-term goal. A Novel Bioactive Lipid Mediated Signaling Pathway 
Putative mechanisms for analgesic and anti-inflammatory actions of NAgly. 1. Inhibition of FAAH elevates anandamide and 2-AG levels (Burstein et al., 2002; Cascio et al., 2004; Huang et al., 2001). 2. Anandamide activates CB1 and CB2 (Axelrod et al., 1998; Barnett-Norris et al., 1998). 3. Receptor activation produces analgesia (Stein et al., 1996; Walker et al., 1999). 4. NAgly binds to PPAR-g (Burstein, 2005). 5. PPAR-g elevates COX-2 expression (Na et al., 2003). 6. COX-2 mediates PGD2 synthesis (Na et al., 2003). 7. Unregulated transformation to PGJ products (Na et al., 2003). 8. PGJ2 promotes resolution of chronic inflammation (Gilroy et al., 1999). 9. Possible positive feedback to PPAR-g (Farnesi-de-Assuncao et al., 2012) 10. NAgly binds to GPR-18 (Burstein et al.,unpublished). 11. Inhibition of forskolin-stimulated adenylate cyclase (Kohno et al., 2006). 12. Activation of phospholipases (Exton, 1996). 13. Release of free arachidonic acid (Burstein et al.,unpublished). 14. Increased lipoxin A4 and PGJ2 synthesis (Burstein et al.,unpublished). 15. Lipoxin A4 promotes resolution of chronic inflammation (Serhan, 2007). Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
Burstein S. "Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum". Mol Pharmacol. 2020 Nov 25. PMID: 33239333.
-
Burstein SH. The Chemistry, Biology and Pharmacology of the Cyclopentenone Prostaglandins. Prostaglandins Other Lipid Mediat. 2020 Jan 10; 106408. PMID: 31931079.
-
Burstein SH. Eicosanoid mediation of cannabinoid actions. Bioorg Med Chem. 2019 May 13. PMID: 31104784.
-
Burstein SH. Ajulemic acid: potential treatment for chronic inflammation. Pharmacol Res Perspect. 2018 Apr; 6(2):e00394. PMID: 29638269.
-
Burstein SH. N-
Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with Therapeutic Potential. Mol Pharmacol. 2018 Mar; 93(3):228-238. PMID: 29138268.
-
Zurier RB, Burstein SH. Cannabinoids, inflammation, and fibrosis. FASEB J. 2016 Nov; 30(11):3682-3689. PMID: 27435265.
-
Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015 Apr 1; 23(7):1377-85. PMID: 25703248.
-
Tepper MA, Zurier RB, Burstein SH. Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity. Bioorg Med Chem. 2014 Jul 1; 22(13):3245-51. PMID: 24856183.
-
Burstein SH. The cannabinoid acids, analogs and endogenous counterparts. Bioorg Med Chem. 2014 May 15; 22(10):2830-43. PMID: 24731541.
-
Burstein SH, Tepper MA. In vitro metabolism and metabolic effects of ajulemic acid, a synthetic cannabinoid agonist. Pharmacol Res Perspect. 2013 Dec; 1(2):e00017. PMID: 25505570.
-
Kattamuri PV, Salmonsen R, McQuain C, Burstein S, Sun H, Li G. Asymmetric synthesis of novel N-(1-phenyl-2,3-dihydroxypropyl)arachidonylamides and evaluation of their anti-inflammatory activity. Life Sci. 2013 Mar 19; 92(8-9):506-11. PMID: 22820546.
-
Burstein S, McQuain C, Salmonsen R, Seicol B. N-Amino acid linoleoyl conjugates: anti-inflammatory activities. Bioorg Med Chem Lett. 2012 Jan 15; 22(2):872-5. PMID: 22217875.
-
Burstein SH, McQuain CA, Ross AH, Salmonsen RA, Zurier RE. Resolution of inflammation by N-arachidonoylglycine. J Cell Biochem. 2011 Nov; 112(11):3227-33. PMID: 21732409.
-
Gao H, Lamusta J, Zhang WF, Salmonsen R, Liu Y, O'Connell E, Evans JE, Burstein S, Chen JJ. Tumor Cell Selective Cytotoxicity and Apoptosis Induction by an Herbal Preparation from Brucea javanica. N Am J Med Sci (Boston). 2011 Apr 25; 4(2):62-66. PMID: 21654932.
-
Tan B, O'Dell DK, Yu YW, Monn MF, Hughes HV, Burstein S, Walker JM. Identification of endogenous acyl amino acids based on a targeted lipidomics approach. J Lipid Res. 2010 Jan; 51(1):112-9. PMID: 19584404.
-
Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009 Mar; 11(1):109-19. PMID: 19199042.
-
Bradshaw HB, Rimmerman N, Hu SS, Burstein S, Walker JM. Novel endogenous N-acyl glycines identification and characterization. Vitam Horm. 2009; 81:191-205. PMID: 19647113.
-
Burstein S, Salmonsen R. Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation. Bioorg Med Chem. 2008 Nov 15; 16(22):9644-51. PMID: 18951802.
-
Stebulis JA, Johnson DR, Rossetti RG, Burstein SH, Zurier RB. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 2008 Nov 7; 83(19-20):666-70. PMID: 18840450.
-
Rimmerman N, Bradshaw HB, Hughes HV, Chen JS, Hu SS, McHugh D, Vefring E, Jahnsen JA, Thompson EL, Masuda K, Cravatt BF, Burstein S, Vasko MR, Prieto AL, O'Dell DK, Walker JM. N-palmitoyl glycine, a novel endogenous lipid that acts as a modulator of calcium influx and nitric oxide production in sensory neurons. Mol Pharmacol. 2008 Jul; 74(1):213-24. PMID: 18424551.
-
Burstein S. The elmiric acids: biologically active anandamide analogs. Neuropharmacology. 2008 Dec; 55(8):1259-64. PMID: 18187165.
-
Ambrosio AL, Dias SM, Polikarpov I, Zurier RB, Burstein SH, Garratt RC. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. J Biol Chem. 2007 Jun 22; 282(25):18625-33. PMID: 17462987.
-
Burstein SH, Adams JK, Bradshaw HB, Fraioli C, Rossetti RG, Salmonsen RA, Shaw JW, Walker JM, Zipkin RE, Zurier RB. Potential anti-inflammatory actions of the elmiric (lipoamino) acids. Bioorg Med Chem. 2007 May 15; 15(10):3345-55. PMID: 17383881.
-
Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem. 2007 Jan 1; 100(1):184-90. PMID: 16927387.
-
Burstein S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci. 2005 Aug 19; 77(14):1674-84. PMID: 16005906.
-
Burstein S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. AAPS J. 2005 Jun 29; 7(1):E143-8. PMID: 16146336.
-
Salim K, Schneider U, Burstein S, Hoy L, Karst M. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology. 2005 Jun; 48(8):1164-71. PMID: 15910892.
-
Burstein S, Zurier RB. Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al. Arthritis Rheum. 2004 Dec; 50(12):4078-9; author reply 4079-80. PMID: 15593192.
-
Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: A novel cannabinoid produces analgesia without a "high". Life Sci. 2004 Aug 6; 75(12):1513-22. PMID: 15240185.
-
Grazia Cascio M, Minassi A, Ligresti A, Appendino G, Burstein S, Di Marzo V. A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun. 2004 Jan 30; 314(1):192-6. PMID: 14715265.
-
Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003 Oct 1; 290(13):1757-62. PMID: 14519710.
-
Bidinger B, Torres R, Rossetti RG, Brown L, Beltre R, Burstein S, Lian JB, Stein GS, Zurier RB. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol. 2003 Aug; 108(2):95-102. PMID: 12921755.
-
Liu J, Li H, Burstein SH, Zurier RB, Chen JD. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol. 2003 May; 63(5):983-92. PMID: 12695526.
-
Zurier RB, Rossetti RG, Burstein SH, Bidinger B. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol. 2003 Feb 15; 65(4):649-55. PMID: 12566094.
-
Burstein SH, Huang SM, Petros TJ, Rossetti RG, Walker JM, Zurier RB. Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem Pharmacol. 2002 Oct 1; 64(7):1147-50. PMID: 12234618.
-
Burstein SH. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr Pharm Des. 2000 Sep; 6(13):1339-45. PMID: 10903396.
-
Burstein SH, Rossetti RG, Yagen B, Zurier RB. Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat. 2000 Apr; 61(1-2):29-41. PMID: 10785540.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2000 | 2 | 2002 | 1 | 2003 | 4 | 2004 | 3 | 2005 | 3 | 2007 | 4 | 2008 | 3 | 2009 | 2 | 2010 | 1 | 2011 | 3 | 2012 | 1 | 2013 | 1 | 2014 | 2 | 2015 | 1 | 2016 | 1 | 2017 | 1 | 2018 | 1 | 2019 | 1 | 2020 | 2 |
To return to the timeline, click here.
For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
|
Burstein's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|